Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share (EWTX)

Historical Holders from Q1 2021 to Q3 2025

Symbol
EWTX on Nasdaq
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
105M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
112M
Holdings value
$1.82B
% of all portfolios
0.004%
Grand Portfolio weight change
0%
Number of holders
171
Number of buys
74
Number of sells
-85
Average Value change %
0%
Average buys %
+0%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share (EWTX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ORBIMED ADVISORS LLC 14.5% $235M 15.3M ORBIMED ADVISORS LLC 09 May 2025
RA CAPITAL MANAGEMENT, L.P. 9.9% $169M 10.4M RA Capital Management, L.P. 30 Sep 2025
BAKER BROS. ADVISORS LP 6.9% $95.2M 7.31M Baker Bros. Advisors LP 30 Jun 2025
BlackRock, Inc. 5.5% $76.4M 5.82M BlackRock, Inc. 30 Jun 2025
JANUS HENDERSON GROUP PLC 4.7% -10% $80.8M -$8.5M 4.98M -9.52% JANUS HENDERSON GROUP PLC 30 Sep 2025
Paradigm Biocapital Advisors LP 5% $73M 4.74M Paradigm BioCapital Advisors LP 27 Jan 2025
PERCEPTIVE ADVISORS LLC 4.4% -28.3% $60.5M -$22.9M 4.64M -27.5% Perceptive Advisors LLC 30 Jun 2025

Institutional Holders of Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share (EWTX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 112M $1.82B -$102M $16.22 171
2025 Q2 119M $1.56B +$135M $13.11 177
2025 Q1 105M $2.32B +$130M $22.00 190
2024 Q4 98.9M $2.64B -$78.9M $26.70 197
2024 Q3 101M $2.7B -$12.1M $26.69 174
2024 Q2 102M $1.83B +$179M $18.01 138
2024 Q1 91.6M $1.67B +$311M $18.24 126
2023 Q4 79.6M $871M +$122M $10.94 115
2023 Q3 68.4M $392M -$8.22M $5.73 84
2023 Q2 69.5M $539M +$23.8M $7.75 94
2023 Q1 66.5M $443M -$749K $6.67 85
2022 Q4 66.5M $594M +$17.7M $8.94 90
2022 Q3 64.4M $634M +$133M $9.84 92
2022 Q2 51M $406M -$30.2M $7.96 76
2022 Q1 54M $524M +$34M $9.70 71
2021 Q4 50.2M $768M +$33.4M $15.28 56
2021 Q3 48M $796M +$3.11M $16.60 47
2021 Q2 46.3M $985M +$40.3M $21.33 45
2021 Q1 45.7M $1.48B +$1.48B $32.50 31